ECE2023 Eposter Presentations Pituitary and Neuroendocrinology (234 abstracts)
Quality of life in acromegaly
Zvezdana Jemuovic 1 , Marina Nikolic Djurovic 1,2 , Sandra Pekic Djurdjevic 1,2 , Dragana Miljic 1,2 , Marko Stojanovic 1,2 , Ana Petakov 1 , Aleksandra Jovanovic 1 , Danica Grujicic 2,3 , Toplica Milojevic 3 , Mihailo Milicevic 2,3 , Aleksandar Stanimirovic 3 , Emilija Manojlovic Gacic 2,4 , Ivana Cekic 1 & Milan Petakov 1,2
1Clinic for Endocrinology, Diabetes and Diseases of Metabolism, University Clinical Center, Department of Neuroendocrinology, Belgrade, Serbia; 2Faculty of Medicine, University of Belgrade, Belgrade, Serbia; 3Clinic for Neurosurgery, University Clinical Center of Serbia, Belgrade, Serbia; 4Institute of Pathology, Belgrade, Serbia.
Introduction: Acromegaly is a rare chronic disease characterized by systemic comorbidity. As a chronic disease, which in most cases requires long-term treatment, it is often accompanied by musculoskeletal, metabolic, and cardiovascular diseases, as well as headaches, anxiety, and depression, which leads to impaired quality of life.
Aim: Assessment of quality of life in patients with acromegaly compared to healthy controls.
Materials and methods: In the study participated 18 patients with active acromegaly (51.7±11.7 years, 38.9% men, 61.1% women) compared to 18 healthy individuals of similar age (48.9±11.5 years, 16.7% men, 83.3% women). Growth hormone in oral glucose tolerance test were determined as well as levels of IGF1. All participants filled out the SF36 quality of life questionnaire. Arithmetic mean±S.D. and Mann–Withney test were used for statistical processing.
Results: We have shown that in the group of patients with acromegaly, IGF1 was elevated 2.53±1.1 times than ULN. 33.3% of patients had hypopituitarism. Examining 8 aspects of health within the SF36 questionnaire, the results showed that subjects with acromegaly had lower average values for each aspect, as well as the total score, compared to the control group, however statistics showed significant difference only in terms of general health (55.22±15.5 vs 75.00±13.3, P<0.001). There was statistically significant difference between the males and females in dimension A /physical functioning/ in favour of the males, which showed higher values (74.57±19.9 vs 55.00±22.0, P<0.001), in dimension B /mental health/ (73.71±15.5 vs 55.36±21.1, P=0.004), as well as in the total SF36 score (76.57±17.5 vs 56.64±21.5, P<0.001).
Conclusions: This is a pilot study in which it was found that patients with acromegaly had lower average results on SF36 questionnaire. Their perception of the general state of health was significantly impaired compared to the control group, which suggests poor quality of life. Further studies are needed to include larger acromegaly population as well as other assessment tests, in order to obtain relevant results and to gain complete insight into the quality of life of these patients.
Article tools
My recent searches
My recently viewed abstracts
Authors
Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 |
Privacy policy |
Cookie settings
BiosciAbstracts
Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.
Find out more